I recommend selling shares of Weight Watchers (SYM: WW) here at $4.50, a 35% loss from our recommended price of $7.01. 
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
The Wall Street Journal calls this new drug “King Kong”…
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
Lot of folks have written in to ask whether I still think Eli Lilly (SYM: LLY) is a buy up here.
This new drug is predicted to help as many as 132 million Americans live longer, healthier and happier lives.
They’re all talking about a new class of weight loss drugs, based on safe and proven diabetes drugs hitting the market: Ozempic, Wegovy and Mounjaro.

deal of the month

best growth stocks

Alliance

Bundle package – lifetime subscriptions for all products

Categories

Recent posts

Tags

Connect with Us

I recommend selling shares of Weight Watchers (SYM: WW) here at $4.50, a 35% loss from our recommended price of $7.01. 
The 30% sell-off in biotech stocks has given us the opportunity to buy things for the best prices I’ve seen all year.
The Wall Street Journal calls this new drug “King Kong”…
The company has strong technology…made even stronger by the fact that NVIDIA invested $50 million in them this past July
Lot of folks have written in to ask whether I still think Eli Lilly (SYM: LLY) is a buy up here.
This new drug is predicted to help as many as 132 million Americans live longer, healthier and happier lives.
They’re all talking about a new class of weight loss drugs, based on safe and proven diabetes drugs hitting the market: Ozempic, Wegovy and Mounjaro.

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.